Outcomes among patients with chronic obstructive pulmonary disease after recovery from COVID-19 infection of different severity

Wang Chun Kwok,Chi Hung Chau,Terence Chi Chun Tam,Fai Man Lam,James Chung Man Ho

DOI: https://doi.org/10.1038/s41598-024-64670-9

IF: 4.6

2024-06-17

Scientific Reports

Abstract:While studies have suggested increased risks of severe COVID-19 infection in chronic obstructive pulmonary disease (COPD), the persistent and delayed consequences of COVID-19 infection on patients with COPD upon recovery remain unknown. A prospective clinical study was conducted in Hong Kong to investigate the persistent and delayed outcomes of patients with COPD who had COVID-19 infection of different severity (mild-moderate COVID-19 and severe COVID-19), compared with those who did not. Chinese patients with COPD ≥ 40 years old were recruited from March to September 2021. They were prospectively followed up for 24.9 ± 5.0 months until 31st August 2023. The primary outcome was the deterioration in COPD control defined as the change in mMRC dyspnea scale. The secondary outcomes included the change in exacerbation frequency and non-COVID-19 respiratory mortality (including death from COPD exacerbation or bacterial pneumonia). 328 patients were included in the analysis. Patients with mild-moderate and severe COVID-19 infection had statistically significant increased risks of worsening of mMRC dyspnoea scale by increase in 1 score from baseline to follow-up with adjusted odds ratios of 4.44 (95% CI = 1.95–10.15, p < 0.001) and 6.77 (95% CI = 2.08–22.00, p = 0.001) respectively. Patients with severe COVID-19 infection had significantly increased risks of increase in severe COPD exacerbation frequency with adjusted odds ratios of 4.73 (95% CI = 1.55–14.41, p = 0.006) non-COVID-19 respiratory mortality from COPD exacerbation or pneumonia with adjusted hazard ratio of 11.25 (95% CI = 2.98–42.45, p < 0.001). After recovery from COVID-19, worsening of COPD control from worsening of dyspnea, increase in severe exacerbation frequency to non-COVID-19 respiratory mortality (COPD exacerbation and pneumonia) was observed among patients with severe COVID-19. Mild to moderate COVID-19 was also associated with symptomatic deterioration.

multidisciplinary sciences

What problem does this paper attempt to address?

The paper aims to explore the persistent and delayed effects of different severities of novel coronavirus disease (COVID-19) on the recovery of patients with chronic obstructive pulmonary disease (COPD). Specifically, the study investigates the worsening of symptoms, increased frequency of acute exacerbations, and non-COVID-19-related respiratory mortality (including deaths due to acute exacerbations of COPD or bacterial pneumonia) in COPD patients after mild to moderate and severe COVID-19 infections through a prospective clinical trial. The study found that both mild to moderate and severe COVID-19 infections significantly increase the risk of worsening scores on the modified Medical Research Council (mMRC) dyspnea scale in COPD patients. Additionally, severe COVID-19 infection is associated with an increased frequency of severe acute exacerbations of COPD and higher non-COVID-19-related respiratory mortality. This indicates that COVID-19 not only affects COPD patients during the acute phase but also has adverse impacts on their long-term health during the recovery phase.